diabetes-symposium - lectures

Ahrén, Prof. B., Sweden Review of safety and efficacy of vildagliptin (LAF237)

Alberti, Prof. Sir G., London, United Kingdom Type 2 Diabetes and CVD - a tale of two diseases?

Armitage, Prof. J., Oxford, United Kingdom The role of Aspirin™ for CV risk reduction in diabetes

Asmar, Prof. R., Paris, France Blood pressure reduction and clinical outcomes - Update from ONTARGET

Bailey, Prof. C., Birmingham, United Kingdom The overall burden of type 2 diabetes

Barnett, Prof. A., Birmingham, United Kingdom Achieving targets safely: role of DPP-4 inhibitors The place of DPP-4 inhibitors in national guidelines – country-specific perspectives Early intervention and long-term renal protection in patients with diabetic nephropathy

Battelino, Prof. T., Slovenia Adolescent Type 2 Diabetes Management and Future Considerations

Beisswenger, Dr. P. J., New Hampshire, United States Postprandial Metabolic Effects: Clinical Implications

Bergenstal, Prof. R., Minneapolis, United States Is SMBG a "must"? – Behavioral change in type 2 diabetes Multitasking: The Path to Effective Diabetes Self-Management The Role of SMBG in Diabetes Management – from Measurement to Therapeutic Action Current debate on the clinical utility of SMBG in patients with T2DM not using insulin and learning Blood Glucose Monitoring as an Integral Part of Diabetes Management Diabetes Management – Today’s Standards

Block, BS, RN J., Stanford, United States Prospective vs retrospective CGM – clinical application and utility

Bode, Prof. B. W., Atlanta, United States Review of home use clinical trial: Clinical application of an interstitial fluid glucose monitor

Bornstein, Prof. S., Dresden, Germany The place of DPP-4 inhibitors in national guidelines – country-specific perspectives

Bosi, Prof. E., Milan, Italy The place of DPP-4 inhibitors in national guidelines – country-specific perspectives

Bugler, Prof. J., Alameda, United States FreeStyle Navigator™ design and technology overview

Buse, Dr. J., North Carolina, United States Target Glycaemic Control: Two Experts` Perspectives

Caduff, Dr. A., Zurich, Switzerland Impedance spectroscopy based glucose monitoring

Cefalu, Dr. W., Pennington, United States Beyond Oral Therapy: Which Insulin to start with?

Ceriello, Prof. A., Udine, Italy Postprandial hyperglycaemia as a driving force in diabetes and CVD Is HbA1c sufficient for the evaluation of hyperglycemia-related CVD risk in diabetes? The metabolic events in the postprandial period Postpranial hyperclycaemia as a driving force in diabetes and CVD - epidemiological evidence & molecular insights Pathophysiology: Diabetes and Cardiovascular Disease Welcome and Introduction Closing Remarks

Charbonnel, Prof. B., Nantes, France The place of DPP-4 inhibitors in national guidelines – country-specific perspectives The Case for Early Combination Therapy in the Management of Type 2 Diabetes

Cherrington, Prof. A., United States The importance of glucagon in glycaemic control: emerging evidence from incretin-based intervention

Chiasson, Prof. J.-L., Montréal, Canada North American Experience Managing Dysglycemia And CVD - Exploring Current Treatment Options Acarbose - a safe and effective treatment choice for pre- and established diabetes with cardiovascular benefits Glucose lowering interventions in diabetes and CVD - lessons from outcome studies Summary and conclusions Glucobay® – treating dysglycaemia and reducing CVD risk Acarbose – a proven role in prediabetes and beyond

Christiansen, Prof. J. S., Aarhus, Denmark What is Normal Glucose? – Continuous Glucose Monitoring Data from Healthy Subjects

Clarke, Prof. W., Charlottesville, United States New perspectives on evaluating continuous monitors for clinical accuracy New perspectives on evaluating continuous glucose monitors for clinical accuracy

Colagiuri, Dr. S., Sydney, Australia Type 2 diabetes – Current guidelines and recommendations

Danne, Prof. T., Hannover, Germany Introduction Continuous glucose monitoring (CGM): the third pillar of glucose management after BGM and HbA1c

Deacon, Dr. C., Denmark Integrating Incretin-Based Therapies In The Treatment Of Type 2 Diabetes

Dekker, Prof. J. M., Netherlands Facing the prediabetes epidemic challenge

Del Prato, Prof. Dr. S., Pisa, Italy Realising the benefits of acarbose across the disease continuum

Diamant, Dr. M., Amsterdam, Netherlands General Diabetes Treatment Principles and Guidelines in Adults

Elliott, MD H. L., Glasgow, United Kingdom Extending the blood pressure - lowering benefits of nifedipine gastrointestinal therapeutic system (GITS) to patients with isolated systolic hypertension (ISH)

Feldman, Dr. B., Alameda, United States FreeStyle Navigator Design and Technology Overview

Feldman, Prof. J., Jerusalem, Israel Dielectrical impedance spectroscopy of biological systems

Ficker, Prof. J., Nuremberg, Germany Epidemiology of Sleep Apnea and Diabetes Mellitus

Fisher, PhD L., University of California, San Francisco, United States Accu-Check 360° View outcome study: Introduction, study design and first results Part 1

Flacke, Dr. F., Zurich, Switzerland Practical aspects of using the Pendra® device

Forst, Prof. T., Mainz, Germany Overview of controlled clinical study results

Frier, Prof. B., Edinburgh, United Kingdom Diabetes and Hypoclycaemia: Have Insulin Analogues Made a Difference

Froguel, Prof. A., London, United Kingdom The RAS and the pathogenesis of diabetes

Füchtenbusch, Dr. M., München, Germany Classification of Diabetes

Gagliardino, Prof. J. J., Argentina Introduction

Garg, Prof. S., Aurora, United States Improving Diabetes Management with Decision Support Tools Improved Management of Insulin Treated Patients with Diabetes First data from ACCU-CHEK Advisor Insulin Guidance Software

Gautier, Prof. J. F., Paris, France Etiology of beta cell dysfunction

Gavin 3rd, Prof. J. R., Atlanta, United States The benefit of SMOOTH blood pressure lowering in diabetic patients

Gerstein, Prof. H. C., Hamilton, Canada Glycemic Control & CVD: What does the Evidence Show? What answers are on the Horizon?

Haffner, Prof. S., San Antonio, United States Acarbose - a first-line therapy to break the CVD connection

Haller, Prof. H., Hannover, Germany Introduction

Hanefeld, Prof. M., Dresden, Germany HbA1c for diagnosis of diabetes: What are we gaining, what are we loosing? Epidemiology: Heart and Diabetes

Harsch, Prof. I., Erlangen-Nuremberg, Germany The Influence of CPAP Therapy in Patients with Diabetes and OSA

Heine, Prof. R., VU University Medical Center, Amsterdam, Netherlands Introduction

Heinemann, Prof. L., Neuss, Germany Concepts to Close the Loop: Will it Become Reality?

Heller, Prof. S., University of Sheffield, Sheffield, United Kingdom Clinical view: what does this mean for our patients?

Hinnen, D., Mid America Diabetes Associates, Wichita, United States Structured Accu-Check 360° View: Its practical applications and therapeutic options

Hirsch, Dr. I. B., Seattle, United States Glycemic Variability and Intensive Insulin Therapy

Holman, Prof. R., Oxford, United Kingdom CVD Risk Reduction In Prediabetes - Impact of Recent Studies and of the ACARBOSE CARDIOVASCULAR EVALUATION (ACE) Trial The new Acarbose Cardiovascular Evaluation (ACE) outcome trial - secondary prevention of CVD in Prediabetes Case Study (including electronic voting) Welcome & Introduction The Acarbose Cardiovascular Evaluation (ACE) study - secondary prevention of CVD in prediabetes Addressing the Diabetes Epidemic: Lessons From the NAVIGATOR Trial A new outcome trial with Glucobay® – further investigation in diabetes and CVD prevention CVD risk reduction in prediabetes – current and future outcome trials

Holst, Prof. J. J., Copenhagen, Denmark Scientific rationale for DPP-4 inhibition Islet Dysfunction in Type 2 Diabetes – The Role of Incretin Hormones The potential of incretin enhancers in the treatment of type 2 diabetes The Incretin Effect in Health and Disease

Home, Prof. P., Newcastle, United Kingdom Requirements for Successful Diabetes Management Beyond Oral Therapy: Which Insulin to start with? State of the Art Diabetes Treatment: Is Step Therapy an Effective Strategy?

Hsu, Dr. W. C., Boston, United States Diabetes epidemic in asian descent - a prespective from the asian american countries

Hu, Prof. D., Peking, China Halting disease progression – the need for early intervention

Hughes, Prof. T. E., United States Pancreatic islet preservation: vildagliptin (LAF237), a novel incretin enhancer, increases ß-cell function and mass in animal models

Hummel, Dr. M., Munich, Germany Diagnosis of Diabetes

Jansen, Dr. J., Amsterdam, Netherlands Meta-analysis of clinical trials

Jellinger, Dr. P., Miami, United States Target Glycaemic Control: Two Experts` Perspectives

Josse, Prof. R., Toronto, Canada Acarbose - safe and effective glycaemic control with cardiovascular benefits Exploring current management options for prediabetes

Jovanovic, Dr. L., Santa Barbara, United States Optimized Diabetes Therapy – Limiting Glycemic Fluctuations Clinical Use of Insulin Analogues in Pregnancy Insulin Delivery and Diabetes Management – Update from Insulin Pump Treatment

Karter, Prof. A., Oakland, United States Effectiveness of SMBG: Findings from a large US Health Care Provider, Kaiser Permanente

Kaufman, MD F., Childrens Hospital Los Angeles, Los Angeles, United States Our Children with Diabetes: Hearts at Risk

Kempler, Prof. P., Budapest, Hungary Autonomic neuropathy: a clinical overview Autonomic neuropathy: a clinical overview

Kerr, Dr. D., Diabetes and Endocrine Centre, Bournemouth, United Kingdom Efficiency of structured SMBG compaired with continuous glucose monitoring

Klonoff, Prof. D. C., San Mateo, United States Overview of the technology and research of continuous glucose monitors

Kolb, Prof. H., Dusseldorf / Neuss, Germany What is the appropriate study design: randomised controlled or observational? Studies about SMBG – Real world versus clinical trials

Kovatchev, Prof. B., Charlottesville, United States Overview of the continuous glucose-error grid analysis (CG-EGA): Advancements and application using Freestyle Navigator data

Kunt, PD Dr. T., Berlin, Germany Intensive Insulin Therapy: Why, When and How to use in Type 2 Diabetes

Kurtz, Prof. W., San Francisco, United States New treatment strategies for insulin resistant patients

Landgraf, Prof. R., Munich, Germany Practical Implications on a National Level

Lefèbvre, Prof. P., Liege, Belgium Panel Discussion

Manes, Dr. C., Thessaloniki, Greece Introduction Evaluation of a new skin test identifying diabetic patients at risk for foot ulceration

Marchetti, Prof. P., Universita di Pisa, Pisa, Italy Progression of Beta-cell Dysfunction and Insulin Resistance

Martin, Prof. S., Dusseldorf, Germany The ROSSO-Trial: Reality of blood glucose monitoring in Germany There is more to glucose monitoring than just HbA1c

Massi-Benedetti, Prof. M., Perugia, Italy The Challenge of Diabetes Management – Normalising Blood Glucose

Matthews, Prof. D., University of Oxford, Oxford, United Kingdom Natural History of Type 2 Diabetes

McGarraugh, Prof. G., Alameda, United States FreeStyle navigator™ Real time continuous glucose monitoring

Meredith, Dr. P. A., Glasgow, United Kingdom Combining antihypertensive drug classes - Extending the evidence and maximising the benefits

Monnier, MD L., Montpellier, France Frequency of self monitoring blood glucose and management of postprandial glucose excursions

Montserrat, Dr. J. M., Barcelona, Spain Managing SDB in high-risk asymptomatic metabolic syndrome

Nauck, Prof. M.A., Bad Lauterberg, Germany Incretin overview: effects of GLP-1

Owens, Dr. D., Llandough Hospital, Penarth, United Kingdom Current debate on the clinical utility of SMBG in patients with T2D not using insulin and learnings

Papanas, Dr. N., Alexandroupolis, Greece Sudomotor dysfunction is associated with duration of Type 2 diabetes mellitus

Peragallo-Dittko, V., New York, United States Translation to Practice

Pfeiffer, Prof. A. F. H., Berlin, Germany Summary and outlook towards the future of glucose monitoring

Pfützner, Prof. A., Mainz, Germany Performance of Pendra® during special situations in diabetes mellitus

Pi-Sunyer, Prof. X., New York, United States Obesity: the role of incretin mimetics in the treatment of Type 2 diabetes

Pinget, Prof. M., Strasbourg, France Clinical Screening of Diabetes for Obstructive Sleep Apnea

Polonsky, MD W. H., San Diego, United States Accu-Chek 360°View outcome study: Introduction, study design and first results New Tools to Assist Non-insulin Treated Patients with Diabetes Accu-Check 360° View outcome study: Introduction, study design and first results Part 2

Punjabi, Prof. N., Baltimore, United States Obstructive Sleep Apnea, Disease Definitions and Metabolic Implications

Reach, Prof. G., Bobigny, France Why do patients hesitate to perform SMBG and how to overcome the barriers?

Renard, Prof. E., Montpellier, France Optimized Diabetes Management with Insulin Pump Treatment

Risse, Dr. A., Dortmund, Germany Neuropathy of the diabetic foot: neo-phenomenological aspects

Rosas, Dr. J., Mexico Latin American Experience

Rosenstock, MD J., Dallas, United States Clinical overview of saxagliptin

Ruilope, Prof. L., Madrid, Spain Nifedipine GITS - a time for ACTION in diabetes patients

Rydén, Prof. L., Stockholm, Sweden The Deadly Duo Dysglycemia And CVD - Recommendations From Current Guidelines Two sides of the same coin - guideline recommendations for managing diabetes and CVD Dysglycaemia and CVD – the deadly duo

Römer von, Dr. Wolf, Munich, Germany Welcome

Satman, Prof. I., Turkey Screening and intervention programmes to prevent diabetes and CVD - an example from daily practice

Scherbaum, Prof. W. A., Dusseldorf, Germany The Value of SMBG for Diabetes Management – Current Evidence Closing remarks

Schikman, MD C. H., Skokie, United States Structured SMBG with Accu-Chek 360°View: Its practical applications and therapeutic options

Schnell, Prof. O., Munich, Germany Hypoglycemia: The neglected complication? Recent guideline recommendations for managing pre- and established diabetes and CVD

Schwarz, Dr. P., Dresden, Germany Education and intervention programs to prevent diabetes and its complications

Scott, Dr. R., New Zealand The Changing Landscape In Type 2 Diabetes Management

Shaw, Dr. J., Australia Asian Experience

Sierra de la, Prof. A., Barcelona, Spain Challenges in treating metabolic syndrome - The advantages of prescribing angiotensin receptor blockers alone and in combination

Snoek, Prof. F., Amsterdam, Netherlands Diabetes Management – "Removing Barries to Self Care" Awareness, Education, Assistance and Action: What to do? Overcoming the Barriers in Implementing Diabetes Management

Spraul, Prof. M., Rheine, Germany Epidemiology and costs of the diabetic foot

Standl, Prof. E., Munich, Germany Type 2 Diabetes: Should it still be considered as an Equivalent of Coronary Heart Disease?! - YES - Type 2 Diabetes: Should it still be considered as an Equivalent of Coronary Heart Disease?! - YES - Rebuttal Cardio-metabolic interactions and side effects of multifactorial risk management Introduction Incretin Enhancement in Type 2 Diabetes – A Vision Metabolic Syndrome – Indicator of a Vascular Catastrophy New Coaching Techniques Treating And Preventing Dysglycemia And CVD - Understanding The Challenge

Standl, Prof. E., Vilsbøll, Dr. T., Nauck, Prof., M., Netherlands Discussion

Tan, Dr. M. H., Indianapolis, United States Welcome Welcome Remarks

Tendolouris, Dr. N., Athens, Greece Usefulness of the indicator plaster neuropad for the diagnosis of peripheral somatic and cardiac autonomic neuropathy in patients with diabetes mellitus

Teschler, Prof. H., Essen, Germany Obstructive Sleep Apnea Diagnosis and Treatment Options

Tschöpe, Prof. D., Bad Oeynhausen, Germany CV benefits of GLP-1 analogues and DPP-IV inhibitors: Fact or myth? Diagnosis of Complications

Tuomilehto, Prof. J., Helsinki, Finland Hypoglycemia as a CV-risk factor European Experience Risk Screening for Diabetes and Cardiovascular Disease Identifying individuals with prediabetes – simple tools for daily practice

Vilsbøll, Dr. T., Copenhagen, Denmark Incretins - The Body´s Own Defensive Player

Wenzel, MAS H., Germany Does SMBG save Money? – Body of current knowledge

Wilding, Prof. J., Liverpool, United Kingdom Sleep Apnoea in the Diabetes Clinic

Wolffenbuttel, Prof. B., Groningen, Netherlands Summary And Conclusion Beyond Oral Therapy: Which Insulin to start with?

Zannad, Prof. F., Nancy, France Introduction: sleep disordered breathing (SDB) and co-morbidities Outcomes of appropriate treatment of SDB in co-morbidities Conclusion

Zick, Prof. R., Lingen, Germany Investigation in dryness of the skin in the diabetic foot syndrome: use of Neuropad, flat electrode- and selective hydrometry

Ziegler, Prof. D., Duesseldorf, Germany New treatment paradigms for diabetic microvascular complications

Zimmet, Prof. P., Mellbourne, Australia Introduction OSA and Type 2 Diabetes: "Partners in Crime" HbA1c for Diagnosis of Diabetes – What are we gaining, what are we losing? Early intervention and treatment of impaired glucose metabolism: The mounting evidence The Metabolic Syndrome: The New Global IDF Criteria

Zinman, Dr. B., Toronto, Canada Chairman Remarks